Cancer Letters
Volume 210, Issue 1 , Pages 27-33 , 8 July 2004

Hypericum perforatum methanolic extract inhibits growth of human prostatic carcinoma cell line orthotopically implanted in nude mice

  • D Martarelli

      Affiliations

    • Department of Pharmacological Sciences and Experimental Medicine, University of Camerino, ViaMarcello Scalzino 3, Camerino (MC) 62032, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39-0737-403314; fax: +39-0737-630618
    • ,
  • B Martarelli

      Affiliations

    • Department of Morphological Sciences and Comparative Biochemistry, Camerino 62032, Italy
    • ,
  • D Pediconi

      Affiliations

    • Department of Pharmacological Sciences and Experimental Medicine, University of Camerino, ViaMarcello Scalzino 3, Camerino (MC) 62032, Italy
    • ,
  • M.I Nabissi

      Affiliations

    • Biosistema S.r.l., 62032 Camerino, Italy
    • ,
  • M Perfumi

      Affiliations

    • Department of Pharmacological Sciences and Experimental Medicine, University of Camerino, ViaMarcello Scalzino 3, Camerino (MC) 62032, Italy
    • ,
  • P Pompei

      Affiliations

    • Department of Pharmacological Sciences and Experimental Medicine, University of Camerino, ViaMarcello Scalzino 3, Camerino (MC) 62032, Italy

Received 5 November 2003 ,Revised 15 January 2004 ,Accepted 16 January 2004.

References 

  1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J. Clin. 1999;(49):8–31
  2. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res. 1990;50:3748–3753
  3. Tenniswood MP, Guenette RS, Lakins J, Mooibroek M, Wong P, Welsh JE. Active cell death in hormone-dependent tissues. Cancer Metastasis Rev. 1992;11:197–220
  4. Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr. Relat. Cancer. 1999;6:503–519
  5. di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer. 1992;70:254–268
  6. Abdul M, Logothetis CJ, Hoosein NM. Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J. Urol. 1995;154:247–250
  7. Abdul M, Anezinis PE, Logothetis CJ, Hoosein NM. Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. Anticancer Res. 1994;14:1215–1220
  8. Schulz V. Clinical trials with hypericum extracts in patients with depression–results, comparisons, conclusions for therapy with antidepressant drugs. Phytomedicine. 2002;9:468–474
  9. Behnke K, Jensen GS, Graubaum HJ, Gruenwald J. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Adv. Ther. 2002;19:43–52
  10. Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int. Clin. Psychopharmacol. 2000;15:61–68
  11. Anonimo, Scheda tecnica: Prozac, Repertorio Farmaceutico Italiano. Farmindustria/Cedof Editore, Milano 2002.
  12. Muller WE, Rolli M, Schafer C, Hafner U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry. 1997;30:102–107
  13. Neary JT, Bu Y. Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes. Brain Res. 1999;816:358–363
  14. Perovic S, Muller WE. Pharmacological profile of hypericum extract. Effect on serotonin uptake by postsynaptic receptors. Arzneimittelforschung. 1995;45:1145–1148
  15. Cott JM. In vivo receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry. 1997;30:108–112
  16. Nahrstedt A, Butterweck V. Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry. 1997;30:129–134
  17. Bennett DA, Phun L, Polk JF, Voglino SA, Zlotnik V, Raffa RB. Neuropharmacology of St. John's Wort (Hypericum). Ann Pharmacother. 1998;32:1201–1208
  18. Calapai G, Crupi A, Firenzuoli F, Costantino G, Inferrera G, Campo GM, et al. Effects of Hypericum perforatum on levels of 5-hydroxytryptamine, noradrenaline and dopamine in the cortex, diencephalon and brainstem of the rat. J. Pharm. Pharmacol. 1999;51:723–728
  19. Kaehler ST, Sinner C, Chatterjee SS, Philippu A. Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rat locus coeruleus. Neurosci. Lett. 1999;262:199–202
  20. Muller WE, Singer A, Wonnemann M, Hafner U, Rolli M, Schafer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry. 1998;31:16–21
  21. Singer A, Wonnemann M, Muller WE. Hyperforin, a major antidepressant constituent of St John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1. J. Pharmacol. Exp. Ther. 1999;290:1363–1368
  22. Hostanska K, Reichling J, Bommer S, Weber M, Saller R. Hyperforin a constituent of St John's wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines. Eur. J. Pharm. Biopharm. 2003;56:121–132
  23. Hostanska K, Reichling J, Bommer S, Weber M, Saller R. Aqueous ethanolic extract of StJohn's wort (Hypericum perforatum L.) induces growth inhibition and apoptosis in human malignant cells in vitro. Pharmazie. 2002;57:323–331
  24. Schempp CM, Kirkin V, Simon-Haarhaus B, Kersten A, Kiss J, Termeer CC, et al.  Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St John's wort that acts by induction of apoptosis. Oncogene. 2002;21:1242–1250
  25. Xie X, Hudson JB, Guns ES. Tumor-specific and photodependent cytotoxicity of hypericin in the human LNCaP prostate tumor model. Photochem. Photobiol. 2001;74:221–225
  26. Begun FP. In:  Lepor H,  Lawson RK editor. Epidemiology and Natural History of Prostate Cancer in Prostate Diseases. Saunders; 1993;
  27. Beynon LL, Busuttil A, Newsam JE, Chisholm GD. Incidental carcinoma of the prostate: selection for deferred treatment. Br. J. Urol. 1983;55:733–736
  28. Tanagho EA, McAninch JW. Smith's General Urology. Appleton e Lange; 1995;
  29. Hoosein NM, Bandyk MG, Nicolson GL, Logothesis CJ, Chung LWK. Espression of neuroendocrine markers and extracellular matrix degradative enzymes in human prostate cells. J. Urol. 1993;149:1066; 479A#1066
  30. Bonkhoff H, Stein U, Remberger K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum. Pathol. 1995;26:167–170
  31. Krijnen JL, Janssen PJ, Ruizeveld de Winter JA, van Krimpen H, Schroder FH, van der Kwast TH. Do neuroendocrine cells in human prostate cancer express androgen receptor?. Histochemistry. 1993;100:393–398
  32. Bonkhoff H, Wernert N, Dhom G, Remberger K. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate. 1991;19:91–98
  33. Grobholz R, Bohrer MH, Siegsmund M, Junemann KP, Bleyl U, Woenckhaus M. Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma. Pathol. Res. Pract. 2000;196:277–284
  34. Whitaker-Azmitia PM, Peroutka SJ. The Neuropharmacology of Serotonin. Ann. N.Y. Acad. Sci. 1990;600:1–715
  35. Seuwen K, Pouyssegur J. Serotonin as a growth factor. Biochem. Pharmacol. 1990;39:985–990
  36. Nemecek GM, Coughlin SR, Handley DA, Moskowitz MA. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc. Natl. Acad. Sci. USA. 1986;83:674–678
  37. Takuwa N, Ganz M, Takuwa Y, Sterzel RB, Rasmussen H. Studies of the mitogenic effect of serotonin in rat renal mesangial cells. Am. J. Physiol. 1989;257:431–439
  38. Tutton PJ, Barkla DH. Biogenic amines as regulators of the proliferative activity of normal and neoplastic intestinal epithelial cells. Anticancer Res. 1987;7:1–12
  39. Nair HK, Rao KV, Aalinkeel R, Mahajan S, Chawda R, Schwartz SA. Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin. Diagn. Lab Immunol. 2004;11:63–69
  40. Bleiker EM, Ploeg HM. Psychosocial factors in the etiology of breast cancer: review of a popular link. Patient Edu. Couns. 1999;37:201–214
  41. Carney CP, Jones L, Woolson RF, Noyes R, Doebbeling BN. Relationship between depression and pancreatic cancer in the general population. Psychosom. Med. 2003;65:884–888
  42. Spiegel D, Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol. Psychiatry. 2003;54:269–282
  43. von Bahr C, Ursing C, Yasui N, Tybring G, Bertilsson L, Rojdmark S. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. Eur. J. Clin. Pharmacol. 2000;56:123–127
  44. Hartter S, Wang X, Weigmann H, Friedberg T, Arand M, Oesch F, et al. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J. Clin. Psychopharmacol. 2001;21:167–174
  45. Shiu SY, Law IC, Lau KW, Tam PC, Yip AW, Ng WT. Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype. J. Pineal. Res. 2003;35:177–182
  46. Siu SW, Lau KW, Tam PC, Shiu SY. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity. Prostate. 2002;52:106–122
  47. Marelli MM, Limonta P, Maggi R, Motta M, Moretti RM. Growth-inhibitory activity of melatonin on human androgen-independent DU 145 prostate cancer cells. Prostate. 2000;45:238–244
  48. Harrer G, Schulz V. Clinical investigation of the antidepressant effectiveness of hypericum. J. Geriatr. Psichiatry Neurol. 1994;7:S6–S8

PII: S0304-3835(04)00134-X

doi: 10.1016/j.canlet.2004.01.031

Cancer Letters
Volume 210, Issue 1 , Pages 27-33 , 8 July 2004

Article Tools

* Image Usage & Resolution